|Day Low/High||0.76 / 0.79|
|52 Wk Low/High||0.64 / 1.20|
The two companies are wholly different, though both give investors reasons for optimism.
Timing is key in investing and EYES shares should pop if a rights offering proves successful for the cash-needy company.
I'm checking out EYES, MITK, ORBC and gold in the early going.
Breadth is running about 2 to 1 negative, and there is weakness in the large-cap FATMAN names.
Now is not the time to buy them, but they have the potential for big moves.
It's unclear whether the market can get into the holiday spirit and produce some upside as we roll into 2017.
With the Fed out of the way, look for traders to be active into the end of the year.
The Fed will be the catalyst for the next market move and, given the technical picture, that could easily be lower.
We have a few more days of this slow trading, and it is unlikely to change much.
Want an antidote for volatility? Do your homework.
Sedate trading is welcome, but there hasn't been an all-clear signal.
Selection of stocks is tailor made for investor, given market parameters.
Today's selling was steady; question is how long it will persist.
Second Sight Medical Products is producing a promising vision restoration device, with more in the pipeline.
You can find flaws with it, but there isn't money to be gained by fighting its strength.